NASDAQ: KMTSKestra Medical Technologies Ltd Stock
$23.54-0.96 (-3.92%)
Updated Apr 21, 2025
KMTS Price
$23.54
Fair Value Price
N/A
Market Cap
$1.21B
52 Week Low
$20.00
52 Week High
$26.15
P/E
N/A
P/B
-4.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.31
Operating Cash Flow
N/A
Beta
0.99
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KMTS Overview
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KMTS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
KMTS
Ranked#38 of 41
Ranked#38 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $4.91 | B | |
| $89.60 | B | |
| $58.31 | B |
Be the first to know about important KMTS news, forecast changes, insider trades & much more!
KMTS News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KMTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KMTS's short-term assets ($69.92M) exceed its short-term liabilities ($38.69M)
Short-term Liabilities Financials
KMTS's short-term assets ($69.92M) exceed its long-term liabilities ($46.69M)
Long-term Liabilities Financials
KMTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more KMTS due diligence checks available for Premium users.
Valuation
KMTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-4.41x
Industry
3.49x
KMTS's financial health
Profit margin
Revenue
$15.1M
Net Income
-$21.8M
Profit Margin
-164.6%
Assets to liabilities
Assets
$108.0M
Liabilities
$85.4M
Debt to equity
-0.31
KMTS's short-term assets ($69.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KMTS's short-term assets ($69.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KMTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KMTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.4M
Investing
-$4.1M
Financing
-$119.0k
KMTS vs Medical Stocks
Kestra Medical Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.